C4 Therapeutics (CCCC) Current Deferred Revenue (2019 - 2026)

C4 Therapeutics' Current Deferred Revenue history runs 8 years deep, the most recent figure standing at $10.1 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 53.1% year-over-year to $10.1 million in Q1 2026; TTM through Mar 2026 was $10.1 million, a 53.1% decrease from a year earlier, with the FY2025 full-year figure at $12.5 million, down 33.24% from the prior year.
• Current Deferred Revenue retreated to $10.1 million in Q1 2026 per CCCC's latest filing, from $12.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $43.8 million in Q2 2025 and bottomed at $8.4 million in Q3 2023.
• The 5-year median for Current Deferred Revenue is $22.2 million (2022), against an average of $25.6 million.
• Across the five-year window, Current Deferred Revenue tumbled 75.86% in 2023 and soared 146.55% in 2024, its largest moves.
• Year by year, Current Deferred Revenue stood at $33.5 million in 2022, then slumped by 53.84% to $15.5 million in 2023, then gained by 20.95% to $18.7 million in 2024, then sank by 33.24% to $12.5 million in 2025, then slipped by 18.96% to $10.1 million in 2026.
• Per Business Quant, the three latest CCCC Current Deferred Revenue figures stand at $10.1 million (Q1 2026), $12.5 million (Q4 2025), and $37.0 million (Q3 2025).